Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Immunotherapy. 2021 Feb;13(3):201-216. doi: 10.2217/imt-2020-0195. Epub 2020 Nov 18.
Psoriasis is a systemic immunologic disorder associated with decreased quality of life and numerous co-morbidities, including psoriatic arthritis and cardiovascular disease. Secukinumab, a fully human IgG1 monoclonal antibody, selectively binds IL-17A and is approved by the US FDA and European Medicines Agency for moderate-to-severe plaque psoriasis and psoriatic arthritis. This review examines the efficacy and safety of secukinumab for the treatment of psoriasis using the literature retrieved from the PubMed database. In clinical trials, treatment with secukinumab led to rapid and sustained improvement in Psoriasis Area and Severity Index (PASI) scores, with PASI 90 response rates up to 68.5% at 5 years. Long-term clinical trial and real-world data have established secukinumab as a safe and effective treatment for psoriasis.
银屑病是一种与生活质量下降和许多合并症相关的系统性免疫紊乱，包括银屑病关节炎和心血管疾病。司库奇尤单抗是一种全人源 IgG1 单克隆抗体，选择性结合 IL-17A，已获得美国食品药品监督管理局和欧洲药品管理局批准，用于治疗中重度斑块型银屑病和银屑病关节炎。本综述通过检索 PubMed 数据库中的文献，考察了司库奇尤单抗治疗银屑病的疗效和安全性。在临床试验中，司库奇尤单抗治疗可迅速且持续改善银屑病面积和严重程度指数（PASI）评分，5 年时 PASI90 应答率高达 68.5%。长期临床试验和真实世界数据证实了司库奇尤单抗治疗银屑病的安全性和有效性。
